Lancet

• Latest
• Best
• Search…

• Lancet · Jul 2018

  Offline: What is science for?

  no abstract available

  read on… or not…

• Lancet · Jul 2018

  Setbacks in the fight to eradicate polio.

  no abstract available

  expand abstract… or just mark as read…

• Lancet · Jul 2018

  Letter

  The how: a message for the UN high-level meeting on NCDs.

  no abstract available

  read more… or not…

• Lancet · Jul 2018

  Editorial

  Cannabinoids: just like any other medication?

  no abstract available

  read more… mark as read…

• Lancet · Jul 2018

  Randomized Controlled Trial Multicenter Study

  Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.

  Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic lupus erythematosus. ⋯ Eli Lilly and Company.

  expand abstract… mark as read…